Vistagen Therapeutics, Inc.
VTGN· Nasdaq
VTGNVistagen Therapeutics, Inc.
Filed Jun 24, 2016 · 10-K · 85 days after period end · 0001415889-16-006331
| Metric | Q4 2016 | Q4 2015 | Q4 2014 | Q4 2010dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | — | — | $352.73K |
| Net Income | -$8.50M | -$6.22M | -$1.83M | -$3.54M |
| EPS Diluted | -$4.44 | -$4.24 | -$1.57 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
ended Mar 31, 2016 · filed Jun 24, 2016 · 85 d after period end
